These data provide evidence that inhibition of RANKL, in this case by its natural inhibitor OPG, can have clinically measurable effects. However, the development of OPG as a therapy for osteoporosis was not pursued because of its potential immunogenicity, because immunologic resistance to OPG could ...
地舒单抗生物类似药 (Celltrion): 一种RANKL抑制剂药物,由Celltrion, Inc. (Celltrion, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: RANKL抑制剂(肿瘤坏死因子配体超家族成员11抑制剂),治疗领域: 肿瘤,内分泌与代谢疾病,皮肤和肌肉骨骼疾病,在研
The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humo... The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hyperc...
In certain aspects, the composition is based on a polypeptide which includes the leading 215 amino acids of the human osteoprotegerin followed by the Fc portion of the human IgGl protein. Pharmaceutical formulations are provided that are suitable for administering the pharmaceutical composition into ...
For the RANKL kit the measurements are validated by no measurable free soluble RANKL when analyzing culture media where a RANKL inhibitor has been added. Furthermore, we have measured the proteins in a range of human body fluids as well as in tissue and cell culture media and the kits work...
(2) to compare the efficacies of the blockade of RANKL/RANK interaction as well as the blockade of NF-κB inhibitor kinase (IKK) and of NF-κB translocation to the nucleus, also in comparison with glucocorticosteroid treatment, in terms of the development of a mouse model of allergic airway...
Enjuanes等[33]研究显示,阿仑膦酸钠通过直接作用于成骨细胞和成骨前体细胞抑制骨吸收,达到治疗骨质疏松的目的;阿仑膦酸钠通过维生素D作用于成骨细胞前体细胞,使得RANKLmRNA表达增高,而OPG在成骨细胞前体细胞分化中未发生改变。Peng等[34]研究发现,锶在骨代谢过程中的破骨细胞和成骨细胞交叉串扰(cross-talk)效应中...
rsRANKL 重组可溶性RANK配体 品牌:O Yeast CAS No.: 储存条件:-80℃ 纯度:– 产品编号 (生产商编号) 等级规格运输包装零售价(RMB)库存情况参考值 303-52191 –20 ug–咨询–– * 干冰运输、大包装及大批量的产品需酌情添加运输费用 * 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因...
Osteoclast differenti- ation factor RANKL controls development of progestin-driv- en mammary cancer. Nature 2010; 468:98-102. 14 Gonzalez-Suarez E, Jacob AP, Jones J, et al RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468:103-107. 15 ...
At least seven signaling pathways are activated by RANK-mediated protein kinase signaling; four of them directly mediate osteoclastogenesis (inhibitor of NF-κB kinase/NF-κB, c-Jun amino-terminal kinase/activator protein-1, c-myc, and calcineurin/nuclear factor of activated T cells [NFAT]c1) ...